Responded to: 16th January 2017
1. In the period of financial year to date:
How many individual funding requests for the usage of Infliximab in the treatment of Hidradentis Suppurativa has the CCG received?
Of the above, is it possible to say how may have been approved?
During the period of April 2016 to December 2016, NHS Stockport CCG has not processed any requests for Infliximab for Hidradentis Suppurativa
2. Are there any gainshare agreements in place between the CCG and a provider (e.g. hospital trust)?
NHS Stockport CCG is currently progressing one gain share in relation to switching Enbrel patients to Benepali biosimilar.
The information supplied to you continues to be protected by the Copyright, Designs and Patents Act 1988. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication, would require the permission of the copyright holder. Most documents supplied by NHS Stockport Clinical Commissioning Group will have been produced by Government officials and will be Crown Copyright.